Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/12/048622
CTRI/2022/12/048622
Recruiting
N/A

Dapagliflozin add-on to metformin in type 2 diabetes mellitus those who are inadequatively controlled on a stable dose of metformin- In Shahjahanpur district population

Aditya kumar0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Aditya kumar
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Aditya kumar

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients with T2DM inadequately controlled with Metformin 1\-2 gm per day
  • •2\. Those patients who are unable to tolerate further increase in further dose of Metformin
  • •3\. Patients aged 30 to 70 years
  • •4\. HbA1C 7\.0% to 9\.0%

Exclusion Criteria

  • •1\. Patient who are on insulin
  • •2\. Patient described any other anti diabetic medication after adding Dapagliflozin to Metformin
  • •3\. Patients in which dose of metformin has to be altered
  • •4\. Patients with renal insufficiency (GFR lress than 30ml/min/1\.73m2\)
  • •5\. Patients who are known case of urinary tract infection , structural abnormalities of urinary tract.
  • •6\. Patients with acute complications of diabetes mellitus
  • •7\. Patients with hypersensitivity to drug

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlType 2 Diabetes
NCT04356742Dong-A ST Co., Ltd.198
Not Yet Recruiting
Phase 3
A study on the effect of Dapagliflozin and Metformin combination on Insulin resistance and cardiovascular disease risk factors in subjects with type II diabetes mellitusHealth Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
CTRI/2023/10/059034S Abissha
Recruiting
Phase 2
A single-site study of the effectiveness of Dapagliflozin for diabetic patients admitted to the intensive care unitDiabetesMetabolic and Endocrine - Diabetes
ACTRN12621001102864Austin Health40
Not Yet Recruiting
N/A
Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liver
JPRN-UMIN000026549Kagawa prefectural central hospital25
Not Yet Recruiting
Phase 4
Comparative effects of dapagliflozin and metformin in obese diabetic patientsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complications
CTRI/2023/11/059814 Shobana